Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

Preclinical data supporting the Phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR-NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML

Monday, April 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses preclinical data supporting the Phase 1 trial design of SENTI-202, a next-generation allogeneic logic-gated selective CAR-NK cell therapy. This innovative therapy aims to overcome key limitations associated with first-generation cell therapies, particularly in the treatment of acute myeloid leukemia (AML). The research was presented at the AACR Annual Meeting.
Price reaction · baseline $3.672 (2024-04-08 close) · hit after-hours · clean, no other SNTI news in the window
day 0 close · peak
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Promising preclinical data for SENTI-202 therapy.
  • Designed to address limitations of first-generation therapies.
  • Focus on acute myeloid leukemia (AML) treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

AACR Annual Meeting Deepika Kaveri, Pearley Chinta, Elizabeth Leitner, Lawrence Naitmazi, Gozde Yucel, Mengxi Tian, Niran Almudhfar, Han Deng, Yongshuai Li, Alice Lam, Chen-Ting Lee, Enping Hong, Rochelle Emery, Brian Garrison, Aaron N. Nguyen, and Kanya Rajangam

Frequently Asked Questions

What is SENTI-202?

SENTI-202 is a next-generation allogeneic logic-gated selective CAR-NK cell therapy.

What limitations does SENTI-202 address?

It aims to overcome key limitations of first-generation cell therapies.

In which disease is SENTI-202 being tested?

SENTI-202 is being tested for the treatment of acute myeloid leukemia (AML).

Where was the data for SENTI-202 presented?

The preclinical data was presented at the AACR Annual Meeting.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare SENTI-202 CAR-NK therapy acute myeloid leukemia preclinical data
Last updated: Apr 8, 2024

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →